
## **Quantitative Systems** Pharmacology Modeling of Loncastuximab **Tesirine Combined With** Mosunetuzumab and **Glofitamab Helps Guide Dosing for Patients With** DLBCL

Yuezhe Li,<sup>1\*</sup> A. Katharina Wilkins,<sup>1</sup> Tim Knab,<sup>1</sup> Joseph P. Boni<sup>2</sup>

<sup>1</sup>Metrum Research Group, Tariffville, CT; <sup>2</sup>ADC Therapeutics America, Murray Hill, NJ



bsAb, bispecific antibody; DLBCL, diffuse large B-cell lymphoma; Glofit, glofitamab; Lonca, loncastuximab tesirine; Mosun, mosunetuzumab; mPBPK, minimal physiologically-based pharmacokinetic; PBD, pyrrolobenzodiazepine; PBPK, physiologically-based pharmacokinetic; QSP, quantitative systems pharmacology.



### **Poster Access**

Copies of this poster obtained through the Quick Response (QR) Code are for personal use only and may not be reproduced without permission from the presenter of this poster.

Poster presented at the AACR Annual Meeting 2024. April 5–10, 2024, San Diego, CA USA

## CONCLUSIONS

- Substantially more tumor growth inhibition (TGI) was predicted to occur at the end of cycle 3 (C3) of loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) + mosunetuzumab (Mosun) combination therapy and at the end of C4 of Lonca + glofitamab (Glofit) than with any of these agents alone
- Increased doses of Lonca in combination therapy regimens were predicted to have limited additional benefit to TGI; however, additional cycles of combination therapy were predicted to enhance TGI
- The examined model suggests that Lonca doses could be reduced to allow for improved tolerability for longer periods of time, up to the point of maximal benefit, although clinical testing is needed to explore these findings
- The ongoing LOTIS-7 clinical study (NCT04970901) evaluates the safety and anticancer activity of Lonca + Mosun and Lonca + Glofit

### INTRODUCTION

- CD19 and CD20, B-lymphocyte surface antigens, are clinically validated therapeutic targets for the treatment of B-cell malignancies<sup>1,2</sup>
- Lonca is an antibody–drug conjugate comprising an anti-CD19 antibody conjugated to a pyrrolobenzodiazepine dimer cytotoxin that is approved as monotherapy for heavily pretreated patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)<sup>3</sup>
- Mosun and Glofit are CD20 × CD3 T-cell–engaging bispecific antibodies (bsAbs) that redirect T cells to eliminate malignant B cells<sup>4,5</sup>
- Mosun and Glofit both target a different B-cell surface antigen than Lonca; hence, combining Lonca with either of these bsAbs is expected to have additive or possibly synergistic efficacy
- Previously, a novel physiologically-based pharmacokinetic (PBPK)–quantitative systems pharmacology (QSP) model was developed<sup>6</sup> and validated with Lonca monotherapy clinical observations in patients with R/R DLBCL<sup>7</sup>

### OBJECTIVE


• To understand how to optimally administer Lonca + Mosun and Lonca + Glofit combination regimens and understand important determinants of exposure leading to the optimal dosing regimen in the context of potentially varying CD19 status

### METHODS

### **Model Construction**

• The Lonca QSP model was based on the previously validated and published Lonca PBPK-QSP model.<sup>6,7</sup> This model was reduced in physiological complexity to be compatible with a published minimal PBPK model of Mosun<sup>8</sup> while maintaining the core functionality of predicting tumor dynamics during Lonca monotherapy (**Figure 1**)

### Figure 1. (A) Integration of Mosun subcutaneous administration into the PBPK-QSP model and (B) Depiction of the QSP model for Lonca + Mosun/Glofit combination therapy



The following parameters were used to model Mosun subcutaneous administration: bioavailability = 0.7; absorption rate = 0.26 day<sup>-1</sup>. Glofit, glofitamab; IL-6, interleukin 6; Lonca, loncastuximab tesirine; Mosun, mosunetuzumab; PBPK, physiologically based pharmacokinetic; QSP, quantitative systems pharmacology.


- The following assumptions were made for integrating the PBPK models:
- Lonca or Mosun/Glofit can induce tumor B-cell killing, though Lonca-killed tumor B cells would linger in the "dying" state. The rate for removing dying tumor B cells was modulated to account for different surface CD19 copy numbers
- The tumor is composed of T cells and malignant B cells (i.e., no healthy B cells)
- Tumor volume is calculated based on the tumor B-cell number (the total of tumor B cells and dying tumor cells) - T cells can enter or leave the tumor as they enter or leave other tissues

### **TGI Modeling**

- The following assumptions and ranges were used to describe potential responses to Lonca + Mosun/Glofit combination therapy:
- ≥80% of the tumor cells are CD19<sup>+</sup>/CD20<sup>+</sup>; the remaining tumor cells are CD19<sup>-/low</sup>/CD20<sup>+</sup>
- CD19<sup>-/low</sup>/CD20<sup>+</sup> tumor cells have 0-1 epitope per cell, resulting in varied susceptibility to Lonca from completely insensitive to somewhat sensitive
- The Lonca-induced maximum killing rate of CD19+/CD20+ tumor cells varied by ±10%
- Initial tumor volume = 1-10 cc
- B-cell proliferation rate = 0.0-0.15 day<sup>-1</sup>
- Lonca was given every 3 weeks (Q3W) at the following doses:
- 150 µg/kg for 2 doses followed by 75 µg/kg
- 120 µg/kg for 2 doses followed by 75 µg/kg
- 90 µg/kg
- Mosun 5 mg on cycle 1 day 1 (C1D1), 45 mg on C1D8, 45 mg on C1D15, and 45 mg Q3W for C2+
- Glofit 2.5 mg on C1D8 following obinutuzumab pretreatment on C1D1, Glofit 10 mg on C1D15, and Glofit 30 mg Q3W for C2+

### Long-Term TGI Modeling Parameters

- Initial tumor volume = 49.5 cc
- The tumor was composed of 100% CD19<sup>+</sup>/CD20<sup>+</sup> malignant B cells
- Initial T-cell:B-cell ratio in tumor = 0.06
- Tumor B-cell proliferation rate = 0.03 day<sup>-1</sup> (tumor doubling time  $\approx$  23 days)
- Tissue B cells and T cells were pre-equilibrated, and no depletion was assumed




# RESULTS

### **QSP Modeling of Lonca + bsAbs**

• Modeling results for Lonca + Mosun (Figure 2) and Lonca + Glofit (Figure 3) both indicated that the addition of Lonca outperformed and showed greater depth of response than either of these bsAbs alone - Both simulations indicated that TGI potential was independent of Lonca dosage


### Figure 2. Tumor growth inhibition of Lonca + Mosun versus Mosun monotherapy



The solid line represents the median of the simulation, and the shaded area represents the 95% CI. CR, complete response; Lonca, loncastuximab tesirine; Mosun, mosunetuzumab; PD, progressive disease; PR, partial response; Q3W, every 3 weeks; SD, stable disease.

• Tumor volume reduction with Mosun monotherapy was predicted to plateau after day 28, whereas Lonca + Mosun combination therapy was predicted to continue to provide TGI (**Figure 4**). Similar results were observed for Glofit monotherapy compared with Lonca + Glofit combination therapy (data not shown)

### Figure 4. Long-term tumor growth inhibition of Lonca + Mosun versus Lonca or Mosun monotherapy



Lonca, loncastuximab tesirine; Mosun, mosunetuzumab.

### Acknowledgments

The analysis was funded by ADC Therapeutics SA and partially funded by Swedish Orphan Biovitrum AB. Medical writing and editorial support, provided by Citrus Health Group (United States), was provided in accordance with Good Publication Practices (GPP 2022) and funded by ADC Therapeutics SA and Swedish Orphan Biovitrum AB.

### **Disclosures**

Y Li: employee of Metrum Research Group. AK Wilkins: employee of Metrum Research Group. T Knab: employee of Metrum Research Group. JP Boni: employee and a current equity holder at ADC Therapeutics America, Inc., a publicly traded company.


**Contact information** 

Yuezhe Li: yuezhel@metrumrg.com

### References

- 1. Bailly S, et al. Hematol Oncol. 2022;40(4):505-517.
- 2. Salles G, et al. Adv Ther. 2017;34(10):2232-2273.
- 3. ADC Therapeutics. ZYNLONTA<sup>®</sup> (loncastuximab tesirine-lpyl) [package insert]. US Food and Drug Administration. 2022.
- 4. Budde LE, et al. *Lancet Oncol*. 2022;23(8):1055-1065.
- 5. Dickinson MJ, et al. *N Engl J Med*. 2022;387(24):2220-2231.
- 6. Utsey K, et al. *Clin Pharmacol Drug Dev.* 2023;12(12):123-125.
- 7. Caimi PF, et al. *eJHaem*. 2023:1-8. Epub ahead of print.
- 8. Hosseini I, et al. NPJ Syst Biol Appl. 2020;6(1):28.






The solid line represents the median of the simulation, and the shaded area represents the 95% CI. CR, complete response; Glofit, glofitamab; Lonca, loncastuximab tesirine; PD, progressive disease; PR, partial response; Q3W, every 3 weeks; SD, stable disease.

• When examined by the total dosage of Lonca received, the TGI provided by Lonca + bsAb combination therapy was predicted to increase with additional cycles of Lonca while being independent of the Lonca dosage level (Figure 5)



### Figure 5. Tumor growth inhibition of Lonca + Glofit by total cumulative Lonca dosage



The horizontal black dashed line represents the no response/partial response separation. Glofit, glofitamab; Lonca, loncastuximab tesirine; Q3W, every 3 weeks.